Adrixetinib (TFA)

• Description :

  Adrixetinib (Q702) TFA is a selective Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity[1][2][3].

• Product Name Alternative :

  Q702 (TFA)

• UNSPSC :

  12352005

• Target :

  C-Fms; TAM Receptor

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/adrixetinib-tfa.html

• Concentration :

  10mM

• Purity :

  99.82

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=NN(CCC)C=C1OCC(F)(F)F)NC2=NC=C(C=C2)OC3=C4C=C(OC)C(OC)=CC4=NC=C3.OC(C(F)(F)F)=O

• Molecular Formula :

  C27H25F6N5O7

• Molecular Weight :

  645.51

• References & Citations :

  [1]WHO Drug Informat ion - World Health Organization (WHO) .|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2